Early Trials of PRMT5 Inhibitors Leave Much to Be Desired, But Optimism Remains
OncLive,
Ulrik N. Lassen, MD Despite the discovery of protein arginine methyltransferase 5 (PRMT5) more than 20 years ago, interest in…
PRT811 Showcases Early Signals of Efficacy in IDH-Mutant Glioma and Uveal Melanoma
OncLive,
Varun Monga, MBBS Phase 1 research indicates that continued investigation with the protein arginine methyltransferase 5 (PRMT5…
PRT811 Yields Early Anti-Tumor Activity in Uveal Melanoma/Advanced Glioma
Cancer Network,
"Preclinical studies demonstrate that IDH1/2 mutations and splicing on mutations such as SF3B1, SRSF2, U2AF1, re-sensitize…
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
OncLive,
Varun Monga, MD The protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 demonstrated preliminary…